Clinical trials: Invasive Carcinoma
NMIBC, TCC
1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors
to compare pathological and oncological outcomes of TURBT versus ERBT in patients with bladder tumors sizes >2.5cm.
- Trial name
- NCT07898033
- Testing
- En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor
- Where
- Israel
- Volunteers
- 136 people
- Sponsor
- dmitry enikeev
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone is a drug which blocks some effects of chemicals called beta-endorphins that are made in the body. Beta-endorphins can be made in response to stress, injury, and also pleasurable activities.
- Conditions
- Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma
- Trial name
- NCT02137252
- Testing
- Naltrexone, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Vulvar Cancer
Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00898352
- Testing
- regional lymph node dissection, radiation therapy
- Sponsor
- Gynecologic Oncology Group
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Bladder Cancer, High Grade
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
This is an expanded access protocol to study the safety and efficacy of CG0070 in Cis and Cis with Ta and/or T1 disease patients who failed both BCG therapy and the BOND protocol (NCT 01438112), or in high grade Ta and T1…
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Trial name
- exBOND (NCT02143804)
- Testing
- oncolytic adenovirus expressing GMCSF
- Where
- United States
- Sponsor
- CG Oncology, Inc.
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
This phase II clinical trial studies how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with advanced, metastatic, or recurrent triple negative invasive breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT01151449
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma
This study is for adult females who have been newly diagnosed with breast cancer that includes surgery as part of standard cancer treatment.
- Trial name
- NCT01816555
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Urothelial Carcinoma Bladder, Androgen Receptor Positive
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs…
- Trial name
- TASUC-Neo (NCT05839119)
- Testing
- Degarelix, Gemcitabine/Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in…
- Conditions
- Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1
- Trial name
- NCT04084730
- Testing
- Accelerated Partial Breast Irradiation
- Where
- 9 sites in United States
- Volunteers
- 280 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NMIBC
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are…
- Trial name
- NCT06810141
- Testing
- rMBCG
- Where
- 66 sites in United States
- Sponsor
- ImmunityBio, Inc.
Non-Muscle Invasive Bladder Cancer (NMIBC)
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- NCT04179162
- Testing
- Bacillus Calmette-Guérin (BCG), Gemcitabine
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary…
- Trial name
- NCT03945162
- Testing
- Ruvidar® (TLD-1433) bladder infusion and PDT
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Theralase® Technologies Inc.
Breast Cancer
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus…
- Trial name
- NCT02137837
- Testing
- Fulvestrant, Anastrozole, Everolimus
- Where
- 223 sites in United States
- Volunteers
- 37 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Recurrent Bladder Cancer
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus Calmette-Guerin (BCG) or chemotherapy…
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
- Trial name
- NCT04917809
- Testing
- Erdafitinib
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Enzalutamide for Bladder Cancer Chemoprevention
The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT02605863
- Testing
- Enzalutamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Rochester
Urothelial Carcinoma
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are…
- Trial name
- NCT03171493
- Testing
- MV-NIS
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vyriad, Inc.
Breast Cancer
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.
- Trial name
- NCT00054301
- Testing
- adjuvant therapy, conventional surgery, intraoperative radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Bladder (Urothelial, Transitional Cell) Cancer
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
This is a prospective, open label, multicenter clinical study of vediximab combined with PD-1 and radiation therapy for bladder preservation in MIBC patients with HER-2 high expression (IHC 2+or 3+), conducted in accordance with…
- Trial name
- DECIDING (NCT07142200)
- Testing
- Disitamab Vedotin, PD-1 inhibitor, radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital
Breast Neoplasms
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
To investigate clinical outcomes, late side effects, and cosmetic results of a single-fraction very accelerated partial breast irradiation as postoperative local treatment for the treatment of early stage breast cancer.
- Trial name
- sfVAPBI (NCT07067437)
- Testing
- single-fraction very accelerated partial breast irradiation
- Where
- 23 sites in France, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- National Institute of Oncology, Hungary
Kidney Neoplasms, Carcinoma, Renal Cell
Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational Study
STUDY DESIGN: prospective multicentric observational SAMPLE SIZE OF THE STUDY: The estimated number of patients to enroll in the multicenter study is at least 270 patients (statistically calculated referring to the results of a…
- Trial name
- NCT05729763
- Testing
- 3D-PADUA nephrometric score, 2D-PADUA nephrometric score
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- San Luigi Gonzaga Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.